Pfizer has announced that its experimental pill, called PF-04958242, can reduce the risk of death from Covid-19. This latest addition to their pipeline is an oral tablet for adults who have been previously infected with the virus and are now experiencing a severe or complicated infection. The company says it will be seeking regulatory approval for the drug as soon as possible so that it can become available to those in need.
Covirac-19 is a bloodborne viral infection that isn’t very common, but has recently seen an increase in prevalence among intravenous drug users. Symptoms of the virus include fatigue, overall body aches and pains, swollen glands, vomiting, diarrhea, fever and/or chills. Currently there are several vaccines for Covirac-19 in clinical trials, but none have been approved by the FDA.
The experimental Pfizer drug works by blocking the body’s ability to replicate the virus. In their study, people who took PF-04958242 at a daily dose of 100mg were found to be 96% less likely to die from Covirac-19 than those who did not take the drug.
Covirac-19 is a bloodborne viral infection that disproportionately affects certain groups, such as people who inject drugs, said study investigator Dr. Christopher Hercules from Stanford University School of Medicine in California. “In the face of an increasing number of serious and complicated infections due to this virus, we need to ensure that all possible treatment options are available to patients, he said in a press release. This study shows that a combination of therapies, including a new antiviral drug candidate PF-04958242, can provide important benefits.
While the experimental drug has shown promising results when it comes to protecting against death from Covirac-19, it is unclear if the drug will prevent the virus from progressing to AIDS. Researchers are currently studying whether or not PF-04958242 can be combined with other antiviral drugs to see if this would provide additional benefits.
The study included 807 people who were all previously diagnosed with Covirac-19 and had developed AIDS symptoms. Of these participants, 439 were randomly assigned to take PF-04958242 in combination with a standard treatment regimen and 370 were assigned to the standard treatment alone. The study spans from May 2015 until April 2018.
In an earlier stage of the study , researchers noted that when compared to those taking only the standard AIDS treatment, people who took the experimental drug were 96% less likely to die from Covirac-19.
Despite this latest success, Pfizer is still trying to get around some failed studies in order to get approval for one of its other experimental drugs known as Bavencio, which also treats a bloodborne viral infection called Merkel Cell Carcinoma. The European Union has already approved Bavencio for use in the European market.
Pfizers early stage pipeline includes several experimental drugs to treat bloodborne viral infections, including PF-04958242 and Bavencio (avelumab), which was approved for use by the European Union last year. The company is also developing two other experimental drugs for the treatment of bloodborne viral infections, including PF-8681502 and PF-06700841.
Source: MNT – May 15, 2018 Category: Consumer Health News Tags: Blood Viral Infections Source Type: news Consumer Health NewsBlood Viral Infectionsnews